$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000114420413043812 Filed on August 08, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$4.802M	$3.531M	$7.103M
YoY Change	-16.7%	-50.29%	136.69%
Cost Of Revenue	$2.276M	$1.632M	$5.118M
YoY Change	-40.7%	-68.11%	315.76%
Gross Profit	$2.526M	$1.899M	$1.985M
YoY Change	31.08%	-4.33%	12.15%
Gross Profit Margin	52.6%	53.78%	27.95%
Selling, General & Admin	$3.900M	$4.000M	$2.500M
YoY Change	85.71%	60.0%	-24.24%
% of Gross Profit	154.39%	210.64%	125.94%
Research & Development	$13.95M	$10.79M	$5.371M
YoY Change	110.0%	100.8%	23.39%
% of Gross Profit	552.18%	567.93%	270.58%
Depreciation & Amortization	$600.0K	$600.0K	$400.0K
YoY Change	50.0%	50.0%	0.0%
% of Gross Profit	23.75%	31.6%	20.15%
Operating Expenses	$13.95M	$10.79M	$5.371M
YoY Change	110.0%	100.8%	23.39%
Operating Profit	-$15.28M	-$12.90M	-$5.855M
YoY Change	123.08%	120.29%	-1.11%
Interest Expense	$64.00K	$45.00K	$3.000K
YoY Change	966.67%	1400.0%	50.0%
% of Operating Profit
Other Income/Expense, Net	-$10.00K		$0.00
YoY Change
Pretax Income	-$15.30M	-$12.63M	-$5.920M
YoY Change	112.0%	113.31%	29.23%
Income Tax		$5.000K
% Of Pretax Income
Net Earnings	-$15.30M	-$12.63M	-$5.920M
YoY Change	112.0%	113.4%	18.57%
Net Earnings / Revenue	-318.62%	-357.77%	-83.35%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.821M	-$1.658M	-$855.1K
COMMON SHARES
Basic Shares Outstanding	152.7M shares	152.5M shares	122.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$146.4M	$40.60M	$26.50M
YoY Change	415.49%	53.21%	18.83%
Cash & Equivalents	$122.5M	$2.574M	$15.33M
Short-Term Investments	$23.90M	$38.00M	$11.20M
Other Short-Term Assets	$365.0K	$20.00K	$261.0K
YoY Change	55.32%	-92.34%	-88.14%
Inventory
Prepaid Expenses	$3.016M	$2.024M	$2.452M
Receivables	$1.911M	$907.0K	$1.498M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$155.0M	$45.37M	$34.98M
YoY Change	324.9%	29.7%	23.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.97M	$13.32M	$7.753M
YoY Change	42.32%	71.8%	2.01%
Goodwill	$58.76M	$33.14M	$33.14M
YoY Change	77.3%	0.0%
Intangibles	$16.41M
YoY Change
Long-Term Investments		$0.00
YoY Change
Other Assets	$164.0K	$335.0K	$350.0K
YoY Change	-53.14%	-4.29%	75.0%
Total Long-Term Assets	$90.05M	$47.55M	$42.00M
YoY Change	104.38%	13.22%	2.69%
TOTAL ASSETS
Total Short-Term Assets	$155.0M	$45.37M	$34.98M
Total Long-Term Assets	$90.05M	$47.55M	$42.00M
Total Assets	$245.1M	$92.92M	$76.98M
YoY Change	204.27%	20.71%	11.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.339M	$2.946M	$3.380M
YoY Change	51.57%	-12.84%	12.67%
Accrued Expenses	$9.553M	$7.223M	$5.633M
YoY Change	58.4%	28.23%	81.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$700.0K	$600.0K	$0.00
YoY Change	250.0%		-100.0%
Total Short-Term Liabilities	$14.26M	$11.26M	$9.422M
YoY Change	36.58%	19.47%	4.69%
LONG-TERM LIABILITIES
Long-Term Debt	$1.900M	$1.900M	$400.0K
YoY Change	90.0%	375.0%	33.33%
Other Long-Term Liabilities	$1.578M	$10.60M	$6.100M
YoY Change	-79.51%	73.77%	60.53%
Total Long-Term Liabilities	$1.578M	$12.50M	$6.500M
YoY Change	-81.86%	92.31%	58.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.26M	$11.26M	$9.422M
Total Long-Term Liabilities	$1.578M	$12.50M	$6.500M
Total Liabilities	$28.50M	$23.69M	$15.90M
YoY Change	48.67%	49.03%	21.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$396.1M	-$380.8M	-$342.9M
YoY Change	13.13%	11.05%
Common Stock	$2.090M	$1.532M	$1.326M
YoY Change	53.68%	15.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.450M	$2.450M	$2.450M
YoY Change	0.0%	0.0%
Treasury Stock Shares	455.4K shares	455.4K shares	455.4K shares
Shareholders Equity	$216.6M	$69.23M	$61.08M
YoY Change
Total Liabilities & Shareholders Equity	$245.1M	$92.92M	$76.98M
YoY Change	204.27%	20.71%	11.08%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$15.30M	-$12.63M	-$5.920M
YoY Change	112.0%	113.4%	18.57%
Depreciation, Depletion And Amortization	$600.0K	$600.0K	$400.0K
YoY Change	50.0%	50.0%	0.0%
Cash From Operating Activities	-$14.90M	-$7.600M	-$6.100M
YoY Change	217.02%	24.59%	-27.38%
INVESTING ACTIVITIES
Capital Expenditures	-$1.600M	-$1.700M	-$300.0K
YoY Change	45.45%	466.67%	50.0%
Acquisitions
YoY Change
Other Investing Activities	$17.00M	-$1.600M	-$4.200M
YoY Change	-374.19%	-61.9%	-166.67%
Cash From Investing Activities	$15.40M	-$3.200M	-$4.500M
YoY Change	-310.96%	-28.89%	-173.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	119.3M	4.400M	12.10M
YoY Change	1512.16%	-63.64%	72.86%
NET CHANGE
Cash From Operating Activities	-14.90M	-7.600M	-6.100M
Cash From Investing Activities	15.40M	-3.200M	-4.500M
Cash From Financing Activities	119.3M	4.400M	12.10M
Net Change In Cash	119.8M	-6.400M	1.500M
YoY Change	-2704.35%	-526.67%	-68.09%
FREE CASH FLOW
Cash From Operating Activities	-$14.90M	-$7.600M	-$6.100M
Capital Expenditures	-$1.600M	-$1.700M	-$300.0K
Free Cash Flow	-$13.30M	-$5.900M	-$5.800M
YoY Change	269.44%	1.72%	-29.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	152718326	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX INC
	dei	Trading Symbol TradingSymbol	NVAX
CY2011Q4	nvax	Additional Tenant Improvement Allowance AdditionalTenantImprovementAllowance	3000000	USD
CY2008Q3	nvax	Common Shares Per Unit CommonSharesPerUnit	1	shares
CY2012Q4	nvax	Common Stock Value Authorized Under Prior Shelf Registration Statement CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement	50000000	USD
	nvax	Deposits For Acquisition Of Property And Equipment DepositsForAcquisitionOfPropertyAndEquipment		USD
	nvax	Deposits For Acquisition Of Property And Equipment DepositsForAcquisitionOfPropertyAndEquipment	500000	USD
CY2013Q2	nvax	Loan Agreement Future Minimum Payments Due LoanAgreementFutureMinimumPaymentsDue	1824000	USD
CY2013Q2	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Four LoanAgreementFutureMinimumPaymentsDueInRollingYearFour	396000	USD
CY2013Q2	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Three LoanAgreementFutureMinimumPaymentsDueInRollingYearThree	571000	USD
CY2013Q2	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Two LoanAgreementFutureMinimumPaymentsDueInRollingYearTwo	571000	USD
CY2013Q2	nvax	Loan Agreement Future Minimum Payments Remainder Of Fiscal Year LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear	286000	USD
CY2013Q3	nvax	Novavax Shares Issued NovavaxSharesIssued	15100000	shares
	nvax	Reclassification From Accounts Payable To Lease Incentives Received ReclassificationFromAccountsPayableToLeaseIncentivesReceived	1100000	USD
	nvax	Reclassification From General Administrative Expenses To Research Development Expenses ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses	400000	USD
CY2013Q1	nvax	Reclassification From General Administrative Expenses To Research Development Expenses ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses	200000	USD
CY2012Q1	nvax	Reclassification From General Administrative Expenses To Research Development Expenses ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses	100000	USD
	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	648000	USD
CY2013Q2	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	255000	USD
	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration		USD
CY2012Q2	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration		USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	450300000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	438939000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1121000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	638000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1176000	USD
CY2011Q4	nvax	Tenant Improvement Allowance TenantImprovementAllowance	2500000	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2946000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3228000	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	907000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1011000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-232000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7223000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7275000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	637000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	430000	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	589000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15832208	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13110708	shares
CY2013Q2	us-gaap	Assets Assets	92918000	USD
CY2012Q4	us-gaap	Assets Assets	102345000	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	45365000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	50408000	USD
CY2013Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38025000	USD
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	32945000	USD
CY2013Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	37388000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	32515000	USD
CY2013Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	38025000	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	26712000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	637000	USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	430000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss		USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss		USD
CY2013Q2	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent		USD
CY2012Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	6233000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1026000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	278000	USD
CY2013Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	60000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	58000	USD
CY2013Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	206000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	237000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2574000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17399000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15334000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14104000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14825000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1230000	USD
CY2008Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	3.62
CY2008Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.5	shares
CY2008Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3343325	shares
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	153165006	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	148398747	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	152709576	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	147943317	shares
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	1532000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	1484000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22423000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12465000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13148000	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5956000	USD
	us-gaap	Contract Revenue Cost ContractRevenueCost	3344000	USD
CY2013Q2	us-gaap	Contract Revenue Cost ContractRevenueCost	1632000	USD
	us-gaap	Contract Revenue Cost ContractRevenueCost	8903000	USD
CY2012Q2	us-gaap	Contract Revenue Cost ContractRevenueCost	5118000	USD
	us-gaap	Contracts Revenue ContractsRevenue	6717000	USD
CY2013Q2	us-gaap	Contracts Revenue ContractsRevenue	3276000	USD
	us-gaap	Contracts Revenue ContractsRevenue	11745000	USD
CY2012Q2	us-gaap	Contracts Revenue ContractsRevenue	7103000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	30267000	USD
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	16429000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	25067000	USD
CY2012Q2	us-gaap	Costs And Expenses CostsAndExpenses	12958000	USD
CY2012Q3	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.1168	pure
CY2012Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2000000	USD
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.121	pure
CY2012Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage Rate Range Minimum DebtInstrumentInterestRateStatedPercentageRateRangeMinimum	0.121	pure
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	34529	USD
CY2012Q3	us-gaap	Debt Instrument Term DebtInstrumentTerm	P42M
CY2013Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	456000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	432000	USD
CY2013Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8077000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6940000	USD
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	258000	USD
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	961000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	810000	USD
CY2013Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		USD
CY2012Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	267000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-40000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	461000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-104000	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4900000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2008Q3	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	2.68
CY2013Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.2	pure
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	267000	USD
CY2013Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	267000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax		USD
CY2012Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-101000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	43000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	19000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6882000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4012000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5537000	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2469000	USD
CY2013Q2	us-gaap	Goodwill Goodwill	33141000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	33141000	USD
CY2011Q1	us-gaap	Government Contract Receivable GovernmentContractReceivable	179000000	USD
CY2013Q2	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	1815000	USD
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2012Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	1570000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-22608000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-12628000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13256000	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5920000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-467000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2101000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-258000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	703000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-702000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-58000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-986000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	245000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	2395000	USD
	us-gaap	Interest Expense InterestExpense	68000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	45000	USD
	us-gaap	Interest Expense InterestExpense	6000	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	3000	USD
	us-gaap	Interest Paid InterestPaid	61000	USD
	us-gaap	Interest Paid InterestPaid		USD
	us-gaap	Investment Income Net InvestmentIncomeNet	95000	USD
CY2013Q2	us-gaap	Investment Income Net InvestmentIncomeNet	48000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	72000	USD
CY2012Q2	us-gaap	Investment Income Net InvestmentIncomeNet	39000	USD
CY2013Q2	us-gaap	Liabilities Liabilities	23692000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	22105000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	92918000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102345000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11256000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11675000	USD
CY2013Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	1653000	USD
CY2012Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	753000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	207000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	168000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	108000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal"> Note 1 - Organization</p> <p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in; font-size-adjust: none; font-stretch: normal"> Novavax, Inc. (the "Company") is a clinical-stage biopharmaceutical company focused on developing recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. The Company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles ("VLPs") and recombinant protein micelle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. The Company's product pipeline targets a variety of infectious diseases with vaccine candidates currently in mid-stage clinical development for seasonal influenza, pandemic influenza and respiratory syncytial virus ("RSV").</p> <!--EndFragment--></div> </div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11572000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19374000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8181000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7798000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18216000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10346000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22630000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-12633000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13256000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-5920000	USD
CY2013Q2	us-gaap	Notes Payable Current NotesPayableCurrent	571000	USD
CY2012Q4	us-gaap	Notes Payable Current NotesPayableCurrent	157000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22902000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12898000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13322000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5855000	USD
CY2013Q2	us-gaap	Other Assets Current OtherAssetsCurrent	20000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	171000	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	335000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	351000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-36000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-458000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-251000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	700000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	5000000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	300000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	300000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	14754000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	9389000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3157000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1076000	USD
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	81000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	167000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	270000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20023000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1500000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	10000000	USD
CY2008Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	17500000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1450000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	100000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-136000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-20000	USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1000	USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-755000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	9649000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	2500000	USD
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2024000	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2559000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> <strong><em>Reclassifications</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Within the June 30, 2012 statement of operations, certain overhead expenses relating to supply chain management of $0.4 million have been reclassified from general and administrative expenses to research and development expenses. Also, within the June 30, 2012 statement of cash flows, additional lease incentives received of $1.1 million recorded in the change in accounts payable and accrued expenses have been reclassified and are included in the change in lease incentives received. All of these reclassifications have been made to conform to current year presentation. In its Quarterly Report on Form 10-Q for the period ended March 31, 2013, the Company had recorded $0.2 million and reclassified $0.1 million of patent costs from general and administrative expenses to research and development expenses for the three months ended March 31, 2013 and 2012, respectively. The Company subsequently determined that patent costs should remain as a general and administrative expense and these costs have been shown as a general and administrative expense for all periods presented herein.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong> </strong></p> <!--EndFragment--></div> </div>
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10018000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13320000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11456000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	29000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations		USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20041000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10785000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10627000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5371000	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue		USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0134	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0096	pure
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	986000	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	757000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	756000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-380793000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-358163000	USD
	us-gaap	Revenues Revenues	7365000	USD
CY2013Q2	us-gaap	Revenues Revenues	3531000	USD
	us-gaap	Revenues Revenues	11745000	USD
CY2012Q2	us-gaap	Revenues Revenues	7103000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1121000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1176000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	33334	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	33334	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y2M27D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7372	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6602	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8048	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7552	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5581	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5581	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7547	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7547	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0059	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0059	pure
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1500000	USD
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4600000	shares
CY2008Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6686650	shares
CY2013Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0154	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0054	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0054	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.00
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.01
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.71
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.71
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4300000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	69226000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	80240000	USD
CY2013Q3	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	218120	shares
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2013Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2013Q3	us-gaap	Unsolicited Tender Offer Costs UnsolicitedTenderOfferCosts	22000000	USD
CY2013Q3	us-gaap	Unsolicited Tender Offer Costs UnsolicitedTenderOfferCosts	140285000	SEK
	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Use of Estimates</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates.</p> <!--EndFragment--></div> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	150391	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	152312	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	123741	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	126925	shares

Files In Submission

Name	View Source	Status
0001144204-13-043812-index-headers.html	Edgar Link	pending
0001144204-13-043812-index.html	Edgar Link	pending
0001144204-13-043812.txt	Edgar Link	pending
0001144204-13-043812-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
nvax-20130630.xml	Edgar Link	completed
nvax-20130630.xsd	Edgar Link	pending
nvax-20130630_cal.xml	Edgar Link	unprocessable
nvax-20130630_def.xml	Edgar Link	unprocessable
nvax-20130630_lab.xml	Edgar Link	unprocessable
nvax-20130630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v350840_10q.htm	Edgar Link	pending
v350840_ex3-1.htm	Edgar Link	pending
v350840_ex31-1.htm	Edgar Link	pending
v350840_ex31-2.htm	Edgar Link	pending
v350840_ex32-1.htm	Edgar Link	pending
v350840_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2013 Q3 Form 10-Q Financial Statement

#000114420413043812 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2013 Q3 Form 10-Q Financial Statement

#000114420413043812 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax